-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $26

Benzinga·03/20/2026 12:40:44
Listen to the news
Guggenheim analyst Debjit Chattopadhyay initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $26.